<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Aug. 16, 2018 (HealthDay News) — Ibalizumab has antiviral activity among patients with multidrug resistant (MDR) HIV-1 infection, according to a study published in the Aug. 16 issue of the New England Journal of Medicine<\/i>.<\/p>\n
Brinda Emu, M.D., from the Yale School of Medicine in New Haven, Conn., and colleagues enrolled 40 adults with MDR HIV-1 infection. A 2,000 mg loading dose of ibalizumab was infused into patients after a seven-day control period in which patients continued to receive their current therapy; the viral load was quantified seven days later. Patients received 800 mg of ibalizumab every 14 days through week 25 of the study.<\/p>\n
Thirty-one patients completed the study. The researchers found that 83 percent of the 40 patients in the intention-to-treat population had a decrease in viral load of at least 0.5 log10<\/sub> copies per milliliter from baseline, with a mean viral-load decrease of 1.1 log10<\/sub> copies per milliliter. Patients who received ibalizumab plus an optimized background regimen had a mean decrease of 1.6 log10<\/sub> copies per milliliter from baseline; 43 percent of the patients had a viral load <50 copies per milliliter and 50 percent had a viral load of <200 copies per milliliter. Nine of the 10 patients who had virologic failure or rebound had a lower degree of susceptibility to ibalizumab than at baseline on in vitro testing.<\/p>\n “In patients with MDR HIV-1 infection who had advanced disease and limited treatment options, ibalizumab had significant antiviral activity during a 25-week study,” the authors write.<\/p>\n The study was funded in part by TaiMed Biologics, the manufacturer of ibalizumab.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Perspective (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n